Table 2. TMB-H Prevalence and OS Analysis by TMB Status.
| Cancer | No. | TMB-H | TMB, median (IQR) | OS (Mo, 95% CI) | HR (95% CI) | ||||
|---|---|---|---|---|---|---|---|---|---|
| No. | % (95% CI) | No.a | TMB-H | Non-TMB-H | Unadjusted | Adjusted | |||
| Total | 2589 | 332 | 12.8 (11.6-14.2) | 2.6 (1.7-6.1) | 2517 | 8.4 (7.4-11.4) | 10.5 (9.5-11.5) | 1.11 (0.93-1.33) | 0.94 (0.77-1.13) |
| SCLC | 305 | 122 | 40.0 (34.7-45.6) | 8.7 (5.2-13.1) | 281 | 6.4 (5.4-7.5) | 7.4 (5.5-10.5) | 1.06 (0.76-1.48) | 1.03 (0.74-1.44) |
| NET | 164 | 48 | 29.3 (22.8-36.6) | 5.2 (2.6-10.4) | 159 | 10.4 (6.4-NA) | 6.4 (4.5-10.5) | 0.81 (0.48-1.39) | 0.83 (0.48-1.44) |
| Cervical | 114 | 17 | 14.9 (9.5-22.6) | 4.4 (2.6-7.0) | 110 | NA (6.4-NA) | 7.4 (4.4-11.5) | 0.31 (0.07-1.27) | 0.32 (0.08-1.31) |
| Anal | 125 | 17 | 13.6 (8.7-20.7) | 4.4 (2.6-7.8) | 119 | 7.4 (2.5-NA) | 7.5 (5.5-15.4) | 0.86 (0.41-1.79) | 0.84 (0.40-1.79) |
| Vulvar | 30 | 4 | 13.3 (5.3-29.7) | 4.1 (2.6-8.1) | 29 | 8.5 (0.5-NA) | 6.5 (2.5-NA) | 1.21 (0.26-5.70) | 1.18 (0.22-6.29) |
| Salivary | 169 | 22 | 13.0 (8.8-18.9) | 1.7 (0.9-4.4) | 164 | 4.5 (3.5-NA) | 15.5 (10.5-21.5) | 1.27 (0.60-2.68) | 1.20 (0.48-2.99) |
| Endometrial | 590 | 66 | 11.2 (8.9-14.0) | 3.5 (1.7-5.2) | 587 | 11.4 (8.5-26.5) | 13.5 (11.5-15.4) | 1.14 (0.75-1.72) | 1.15 (0.75-1.75) |
| Biliary | 706 | 28 | 4.0 (2.8-5.7) | 2.6 (0.9-3.5) | 697 | 11.5 (7.4-NA) | 8.4 (7.4-10.4) | 0.71 (0.39-1.29) | 0.65 (0.35-1.19) |
| Thyroid | 223 | 6 | 2.7 (1.2-5.7) | 1.7 (0.9-3.5) | 220 | 10.2 (1.5-NA) | 27.5 (21.5-NA) | 1.70 (0.41-7.02) | 1.64 (0.39-6.96) |
| Mesothelioma | 163 | 2 | 1.2 (0.3-4.4) | 1.7 (0.9-2.6) | 151 | NA | 12.5 (8.5-15.5) | NA | NA |
Abbreviations: HR, hazard ratio; IQR, interquartile range; NA, not available/applicable; NET, neuroendocrine tumor; OS, overall survival; SCLC, small cell lung cancer; TMB, tumor mutational burden; TMB-H, high TMB.
a
Patients were excluded from OS analysis if the start of immunotherapy was earlier than or equal to FMI report date (69 patients) or had death date prior to January 1, 2012 (3 patients).